• Cleveland skyline with ITP Conference logo
  • ITP Registry
  • Group photo of PDSA staff and ITP patients
  • REGISTRATION IS OPEN

    18th National Patient Conference - July 13-15, 2018. Together we will rock Cleveland, Ohio as we celebrate PDSA's 20th anniversary!
    More Info
  • ITP Registry

    Register to advance research and improve the quality of life for ITP patients.
    More Info
  • The Power of Membership

    Make a difference in the lives of those living with ITP and receive the 28-page Platelet News.
    More Info
Two girls hugging a tree

Find Support Near You

PDSA offers support groups across the United States and Canada—and new groups continue to form. Get involved, get support and help others.

More Info...

Holding hands

Connect with Others

PDSA is a community built for you or your loved one with ITP. Find answers on our private discussion group with thousands of members.

More Info...




Man using tablet computer outside

ITP in the News

Read the latest news about ITP—from breaking updates and survivor stories, to in-depth insights into new treatments and cutting-edge research.

More Info...

Girl wearing purple shirt for Sport Purple for Platelets Day

ITP Awareness

Each September we celebrate ITP Awareness Month℠! Learn how you can join the party to support ITP Awareness Month, Sport Purple for Platelets Day℠ and many other events throughout the United States and world. Participate to elevate ITP awareness and support funding of ITP research and PDSA programs.

More Info...

ITP News & Information

  • Novartis’ severe aplastic anaemia drug fast-tracked by FDA

    Novartis’ severe aplastic anaemia drug fast-tracked by FDA

    "The FDA has accepted Novartis’ supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of severe aplastic anaemia (SAA), a rare and serious blood condition.

    Priority Review designation is used for treatments that address a serious or life-threatening disease or condition

  • Young man with ITP donates power chargers to hospital patients

    Young man with ITP donates power chargers to hospital patients

    "One young man is on a mission to gather as many power chords as possible for children who are hospitalized.

    It's called Power Jacks, which only makes sense because it was created by 13 year-old Jack Lewy.

    Lewy is no stranger to Tulane Lakeside Hosptial for Women and Children in Metairie.

    In December, Lewy suffered

  • Novartis’ Revolade proved effective for seniors

    Novartis’ Revolade proved effective for seniors

    "Novartis Korea said Tuesday additional data analysis from its EXTEND clinical trial for Revolade (ingredient: eltrombopag) proved it safe and effective for those 65 years and older with idiopathic thrombocytopenic purpura (ITP).

    The sub-set study findings were presented at the first International Congress of BMT symposium held in Seoul on Aug. 26.

    Revolade (known as

  • Protalex Doses First Patient in Third Cohort of European Phase 1b Study of PRTX-100 in ITP

    Protalex Doses First Patient in Third Cohort of European Phase 1b Study of PRTX-100 in ITP

    "Protalex, Inc., a clinical-stage biopharmaceutical company, today announced that following a planned interim analysis of data from the second dose cohort of its European Phase 1b study of PRTX-100 in adults with persistent/chronic Immune Thrombocytopenia (ITP) (PRTX-100-203 Study), the Company has initiated enrollment in the third cohort of this dose-escalating study. The first patient in

  • 1
  • 2
  • 3
  • 4
  • 5

BBB Cleveland logoGuideStar Seal - 2017 goldNORD Member Badge 2018THSNA logo


Thank you to our sponsors for supporting the PDSA Website

Amgen logo